Hikma appoints new President of Injectables business

London, 9 August 2023 - Hikma Pharmaceuticals PLC and its subsidiaries ('Hikma' or 'Group'), the multinational pharmaceutical company, announce that Dr. Bill Larkins has been appointed President of its Injectables business, effective 1 September 2023. Bill will be based in the US and report to Riad Mishlawi in his new role as Hikma's Chief Executive Officer.

Bill has extensive experience in the sterile injectable generic market. He was previously Chief Executive Officer of Custopharm, which was acquired by Hikma in 2022 and has since been Hikma´s Senior Vice President, R&D, Injectables.

During his career, Bill has held senior leadership roles at leading injectable pharmaceutical companies including Bedford Laboratories and ESI Lederle/Baxter. He also played a significant role at Schein Pharmaceuticals' Steris Laboratories in Phoenix and at Amylin Pharmaceuticals, where he worked on the development of complex injectable medicines.

Commenting on the appointment, Riad Mishlawi, President of Injectables / CEO-elect said: "Bill's exceptional leadership skills, vast expertise, and successful track record make him the ideal person to lead our Injectables team. Over the next few years, we have a tremendous opportunity to further expand Hikma's position as a market-leading manufacturer and supplier of generic injectable medicines. I look forward to working with Bill in his new role."

Dr. Bill Larkins added: "This is a very exciting opportunity for me to lead a highly talented team, who have been growing and developing this business so successfully over the years. I am confident that we can continue to leverage our differentiated R&D pipeline, capacity expansion projects and new businesses to further enhance our position as one of the leading providers of injectable medicines across our geographies."

- ENDS -

Hikma (Investors):                           

Teneo (Press):                                                                     

Charles Armitstead / Rob Yates                           +44 (0)7703 330269/ +44 (0)7715 375443          

About Hikma:

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,700 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P and BBB-/positive Fitch)